Regulations for Testing and Licensing of Vaccines in United Kingdom
M. Ranjitha
Pharmaceutical Regulatory Affairs Group, Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru – 570015, Karnataka, India.
H. R. Arjun
Pharmaceutical Regulatory Affairs Group, Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru – 570015, Karnataka, India.
M. P. Venkatesh *
Pharmaceutical Regulatory Affairs Group, Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru – 570015, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Vaccines are one of the most significant achievements of science and public health for prevention of infectious disease. Overall vaccination policies for HCP in should be periodically revaluated in order to provide optimal protection against vaccine preventable diseases and infection control with in healthcare. The guidelines address ethical issues that arise during a vaccine study. A network of Adverse Drug Reaction (ADR) monitoring centre alone with adverse event following immunisation (AEFI) provide the machinery for vaccine pharmacovigilance.
Keywords: Vaccine pharmacovigilance, adverse drug reaction, adverse event following immunization, vaccine preventable disease